Machine Learning LGG Subtype Classification via Morphometric Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating lower-grade gliomas (LGGs) are hindered by their heterogeneity at histopathological and molecular levels, leading to significant variability in clinical outcomes, and existing technologies fail to accurately stratify patients for personalized treatment.
Innovation Solution
A method using machine learning to determine LGG subtypes by analyzing cellular morphometric biomarkers from whole-slide images, which involves obtaining a tissue sample, identifying cellular morphometric subtypes, and tailoring treatment with immunotherapy based on subtype classification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional histopathological and molecular methods are used for LGG classification, then diagnostic procedures are well-established, but the heterogeneity of LGGs leads to significant variability in clinical outcomes and inaccurate patient stratification
Solution Approach 1:
The patent replaces traditional mechanical histopathological examination and molecular testing with an optical/image-based machine learning system. The framework extracts cellular morphometric features from routine H&E-stained whole-slide images using deep learning algorithms, substituting conventional diagnostic mechanisms with computational image analysis to achieve more consistent and accurate patient stratification across the heterogeneous LGG population
Solution Approach 2:
The patent changes the diagnostic parameters from traditional histopathological descriptions and molecular markers to quantitative cellular morphometric features extracted by machine learning. The system measures numerous cellular properties (nuclear size, shape, chromatin pattern, cellular arrangement) that are then used to define molecularly-agnostic subtypes, transforming the basis of classification into a more reliable set of parameters that cut through LGG heterogeneity
2Extent of automation
If deep neural networks are applied to glioma studies, then automated analysis capability is improved, but quantitative profiling and molecular association of cellular morphometric landscape remain inadequately investigated due to technical and conceptual limitations
Solution Approach 1:
The patent introduces cellular morphometric features as an intermediary between routine histopathological images and molecular characteristics. The machine learning framework extracts these intermediate features that capture morphological information correlated with molecular subtypes, bridging the gap between visual histology and molecular biology without requiring direct molecular testing, thus preserving molecular association information while maintaining automation
Solution Approach 2:
The patent performs preliminary extraction of cellular morphometric features from routine H&E images before any molecular analysis or clinical decision-making. This preliminary automated analysis establishes a morphometric profile that can be correlated with molecular subtypes and used to guide subsequent targeted molecular testing or treatment decisions, maximizing the use of already-available image data
3Ease of operation
If LGG patients are treated with uniform protocols, then treatment simplicity is maintained, but the heterogeneity at histopathological and molecular levels results in significant variability in clinical outcomes
Solution Approach 1:
The patent segments the heterogeneous LGG population into distinct molecularly-agnostic subtypes based on cellular morphometric features extracted from routine histopathological images. This segmentation divides patients into groups with more homogeneous characteristics and predicted responses to treatment, allowing clinicians to apply targeted treatment protocols to each subtype rather than uniform treatment to all, thereby improving outcome consistency while maintaining operational feasibility
Solution Approach 2:
The patent applies the concept of local quality by tailoring treatment approaches to specific LGG subtypes identified through morphometric analysis. Instead of uniform treatment protocols, the system enables localized treatment strategies optimized for each subtype's characteristics, improving the match between treatment and patient-specific tumor biology while maintaining the simplicity of algorithmic classification
Data Source
AI summary
A method for determining a Lower Grade Glioma (LGG) subtype for a subject. A device for determining an LGG subtype in a subject. A system using machine learning for determining a Lower Grade Glioma (LGG) subtype in a subject.